BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50. [PMID: 27186144 DOI: 10.2147/hmer.s74612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Moore AH. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. Clin Liver Dis (Hoboken) 2019;14:183-6. [PMID: 31879561 DOI: 10.1002/cld.860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ghoneim S, Butt MU, Trujillo S, Asaad I. FIB-4 Regression With Direct-Acting Antiviral Therapy in Patients With Hepatitis C Infection: A Safety-Net Hospital Experience. Front Med (Lausanne) 2020;7:359. [PMID: 32793612 DOI: 10.3389/fmed.2020.00359] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang L, Yu Q, Wang J. Association Between Changes in Splanchnic Hemodynamics and Risk Factors of Portal Venous System Thrombosis After Splenectomy with Periesophagogastric Devascularization. Med Sci Monit 2018;24:4355-62. [PMID: 29937539 DOI: 10.12659/MSM.909403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Moeini A, Machida H, Takiuchi T, Blake EA, Hom MS, Miki T, Matsuo O, Matsuo K. Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer. Clin Appl Thromb Hemost 2017;23:1018-27. [PMID: 27582024 DOI: 10.1177/1076029616665925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in Virus Infections. J Clin Med 2021;10:877. [PMID: 33672766 DOI: 10.3390/jcm10040877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
6 Gudowska M, Wrona A, Gruszewska E, Panasiuk A, Cylwik B, Swiderska M, Filisiak R, Szmitkowski M, Chrostek L. Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases. Clin Exp Hepatol 2016;2:149-54. [PMID: 28856280 DOI: 10.5114/ceh.2016.63872] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Sigal SH, Sherman Z, Jesudian A. Clinical Implications of Thrombocytopenia for the Cirrhotic Patient. Hepat Med. 2020;12:49-60. [PMID: 32341665 DOI: 10.2147/hmer.s244596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
9 Gotlieb N, Schwartz N, Zelber-Sagi S, Chodick G, Shalev V, Shibolet O. Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis. World J Gastroenterol 2020; 26(38): 5849-5862 [PMID: 33132639 DOI: 10.3748/wjg.v26.i38.5849] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc 2020;9:e016441. [PMID: 32885738 DOI: 10.1161/JAHA.120.016441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Yoshida M, Tateishi R, Hiroi S, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data. Adv Ther 2021. [PMID: 34928469 DOI: 10.1007/s12325-021-02008-x] [Reference Citation Analysis]
12 Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 2019;10:293. [PMID: 30873165 DOI: 10.3389/fimmu.2019.00293] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
13 Chen Y, Cai N, Lai Y, Xu W, Li J, Huang L, Huang Y, Hu M, Yang H, Chen J. Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia. Front Pharmacol 2020;11:1137. [PMID: 32792958 DOI: 10.3389/fphar.2020.01137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol 2020;2020:5421632. [PMID: 32047671 DOI: 10.1155/2020/5421632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med 2020;63:188-97. [PMID: 32884438 DOI: 10.33160/yam.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, Shatzel JJ. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets 2021;:1-7. [PMID: 33459573 DOI: 10.1080/09537104.2020.1859102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Zhao HM, Zhang XY, Lu XY, Yu SR, Wang X, Zou Y, Zuo ZY, Liu DY, Zhou BG. Erzhi Pill® Protected Experimental Liver Injury Against Apoptosis via the PI3K/Akt/Raptor/Rictor Pathway. Front Pharmacol 2018;9:283. [PMID: 29636693 DOI: 10.3389/fphar.2018.00283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol 2018; 24(46): 5271-5279 [PMID: 30581275 DOI: 10.3748/wjg.v24.i46.5271] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
19 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 39] [Article Influence: 54.0] [Reference Citation Analysis]
20 Reusswig F, Fazel Modares N, Brechtenkamp M, Wienands L, Krüger I, Behnke K, Lee-Sundlov MM, Herebian D, Scheller J, Hoffmeister KM, Häussinger D, Elvers M. Efficiently Restored Thrombopoietin Production by Ashwell-Morell Receptor and IL-6R Induced Janus Kinase 2/Signal Transducer and Activator of Transcription Signaling Early After Partial Hepatectomy. Hepatology 2021;74:411-27. [PMID: 33369745 DOI: 10.1002/hep.31698] [Reference Citation Analysis]
21 Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res 2019;49:1169-81. [PMID: 31228221 DOI: 10.1111/hepr.13392] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zanetti M, Scatolin M, Oltramari AR, Lopes MLLDC, Zeferino RCF, Colpani GL, Müller LG, de Oliveira D, Fiori MA. Antifungal Activity and Acute and Repeated-Dose Toxicity Study of Geranyl Cinnamate Ester in Mice. Evid Based Complement Alternat Med 2021;2021:3493625. [PMID: 34659431 DOI: 10.1155/2021/3493625] [Reference Citation Analysis]
23 Desai S, Subramanian A. Thrombocytopenia in Chronic Liver Disease: Challenges and Treatment Strategies. Cureus 2021;13:e16342. [PMID: 34277309 DOI: 10.7759/cureus.16342] [Reference Citation Analysis]
24 Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 2021;11:643815. [PMID: 34367949 DOI: 10.3389/fonc.2021.643815] [Reference Citation Analysis]
25 Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz Ž, Štabuc B, Trifan A. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med 2021;10:5419. [PMID: 34830701 DOI: 10.3390/jcm10225419] [Reference Citation Analysis]
26 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 91] [Article Influence: 64.0] [Reference Citation Analysis]
27 Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Hashiguchi T, Imoto Y. Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:9142672. [PMID: 30050894 DOI: 10.1155/2018/9142672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Li C, Li X, Huang F, Yang J, Wu A, Wang L, Qin D, Zou W, Wu J. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2019;10:829. [PMID: 31402863 DOI: 10.3389/fphar.2019.00829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Khalifa A, Rockey DC. Lower Gastrointestinal Bleeding in Patients With Cirrhosis-Etiology and Outcomes. Am J Med Sci 2020;359:206-11. [PMID: 32087941 DOI: 10.1016/j.amjms.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gunda DW, Kilonzo SB, Mamballah Z, Manyiri PM, Majinge DC, Jaka H, Kidenya BR, Mazigo HD. The magnitude and correlates of esophageal Varices among newly diagnosed cirrhotic patients undergoing screening fibre optic endoscope before incident bleeding in North-Western Tanzania; a cross-sectional study. BMC Gastroenterol 2019;19:203. [PMID: 31783802 DOI: 10.1186/s12876-019-1123-9] [Reference Citation Analysis]
31 Saab S, Brown RS Jr. Management of Thrombocytopenia in Patients with Chronic Liver Disease. Dig Dis Sci. 2019;64:2757-2768. [PMID: 31011942 DOI: 10.1007/s10620-019-05615-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
32 Shirley M, McCafferty EH, Blair HA. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure. Drugs 2019;79:1689-95. [PMID: 31529283 DOI: 10.1007/s40265-019-01197-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Nhinda NT, Segamwenge IL, Nampweya T, Engels C. Spontaneous gastrocnemius muscle haematoma formation in a patient with alcoholic liver disease. Pan Afr Med J 2020;36:348. [PMID: 33224414 DOI: 10.11604/pamj.2020.36.348.24623] [Reference Citation Analysis]
35 Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol 2021;7:172-7. [PMID: 34295984 DOI: 10.5114/ceh.2021.106864] [Reference Citation Analysis]
36 Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med 2019;18:596-604. [PMID: 31258695 DOI: 10.3892/etm.2019.7616] [Reference Citation Analysis]
37 Li X, Xu H, Gao P. Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center. Med Sci Monit 2020;26:e927946. [PMID: 33180750 DOI: 10.12659/MSM.927946] [Reference Citation Analysis]
38 Knaak C, Schuster FS, Nyvlt P, Heeren P, Spies C, Schenk T, La Rosée P, Janka G, Brunkhorst FM, Lachmann G. Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients. PLoS One 2021;16:e0254345. [PMID: 34252125 DOI: 10.1371/journal.pone.0254345] [Reference Citation Analysis]
39 Lelei-Mailu FJ, Mariara CM. Pregnancy in a patient with portal hypertension secondary to liver cirrhosis. BMJ Case Rep 2018;2018:bcr-2017-223076. [PMID: 29507022 DOI: 10.1136/bcr-2017-223076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Gura KM, Premkumar MH, Calkins KL, Puder M. Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study. J Pediatr 2021;230:46-54.e2. [PMID: 33038344 DOI: 10.1016/j.jpeds.2020.09.068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Dig Dis 2021;39:234-42. [PMID: 32759604 DOI: 10.1159/000510692] [Reference Citation Analysis]
42 Mataya LA, Srinivasan V, Rand EB, Alcamo AM. Multiple organ involvement and ICU considerations for the care of acute liver failure (ALF) and acute on chronic liver failure (ACLF) in children. Transl Pediatr 2021;10:2749-62. [PMID: 34765498 DOI: 10.21037/tp-20-375] [Reference Citation Analysis]
43 Rani GF, Preham O, Ashwin H, Brown N, Hitchcock IS, Kaye PM. Dissecting pathways to thrombocytopenia in a mouse model of visceral leishmaniasis. Blood Adv 2021;5:1627-37. [PMID: 33710338 DOI: 10.1182/bloodadvances.2020004082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci 2020;21:E3294. [PMID: 32384725 DOI: 10.3390/ijms21093294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Miki N, Inoue S, Shibahara H, Kurazono K, Perard R, Tateishi R. A cost-effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan. JGH Open 2021;5:879-87. [PMID: 34386595 DOI: 10.1002/jgh3.12597] [Reference Citation Analysis]
46 Giannini EG, Kano T, Ochiai T, Bentley R, Shrestha P, Afdhal N. Bleeding events in lusutrombopag-treated thrombocytopenic patients. Eur J Clin Invest 2021;51:e13503. [PMID: 33523482 DOI: 10.1111/eci.13503] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Scharf RE. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management. J Clin Med 2021;10:1530. [PMID: 33917431 DOI: 10.3390/jcm10071530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Balaphas A, Meyer J, Sadoul K, Fontana P, Morel P, Gonelle-Gispert C, Bühler LH. Platelets and Platelet-Derived Extracellular Vesicles in Liver Physiology and Disease. Hepatol Commun 2019;3:855-66. [PMID: 31304449 DOI: 10.1002/hep4.1358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
49 Gunathilake V, Bertolino M, Bavestrello G, Udagama P. Immunomodulatory Activity of the Marine Sponge, Haliclona (Soestella) sp. (Haplosclerida: Chalinidae), from Sri Lanka in Wistar Albino Rats: Immunosuppression and Th1-Skewed Cytokine Response. J Immunol Res 2020;2020:7281295. [PMID: 33274242 DOI: 10.1155/2020/7281295] [Reference Citation Analysis]
50 Shimizu R, Katsube T, Wajima T. Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease. CPT Pharmacometrics Syst Pharmacol 2021;10:489-99. [PMID: 33797208 DOI: 10.1002/psp4.12623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gaur K, Puri V, Agarwal K, Suman S, Dhamija RK. Chronic Liver Disease Presenting as Immune Hemolytic Anemia: The Challenges of Diagnosis in the Critically Ill in a Resource-Limited Health Care Setting. Cureus 2021;13:e14880. [PMID: 34104606 DOI: 10.7759/cureus.14880] [Reference Citation Analysis]
52 Kamarul Bahrin MH, Vijayenthiran H, Stimson L, Ahmad H. Persistent Immune Thrombocytopenia Resistant to Immunosuppressive Therapy: What Is the Way Forward? Cureus 2020;12:e12377. [PMID: 33527058 DOI: 10.7759/cureus.12377] [Reference Citation Analysis]
53 O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, Asiki G, Seeley J, Matthews PC, Newton R. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open 2020;10:e032890. [PMID: 32234740 DOI: 10.1136/bmjopen-2019-032890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Zhong Y, De T, Alarcon C, Park CS, Lec B, Perera MA. Discovery of novel hepatocyte eQTLs in African Americans. PLoS Genet 2020;16:e1008662. [PMID: 32310939 DOI: 10.1371/journal.pgen.1008662] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]